HBM HOLDINGS-B (02142.HK): AI Drug LET003 Gets IND Nod in China
NewTimeSpace News: On 19 November 2026, HBM Holdings Limited (stock code: 02142) announced on a voluntary basis that China's National Medical Products Administration has accepted the investigational new drug application for LET003, a new-generation monoclonal antibody targeting ACVR2A/2B developed using the company's Hu-mAtrIx AI platform, for the treatment of overweight or obesity.
LET003 is a potential best-in-class monoclonal antibody targeting the activin receptors ACVR2A and ACVR2B, which play a key role in regulating muscle and fat metabolic homeostasis. It is the company's first AI-enabled drug candidate and works through dual-target blockade of ACVR2A and ACVR2B.
Preclinical studies show that LET003 has a pharmacokinetic profile superior to several comparable molecules. When used in combination with semaglutide, LET003 significantly enhances fat reduction while effectively preserving lean body mass. The antibody also achieves lean mass promotion comparable to high-dose bimagrumab at lower dose levels.
The company issued the warning statement required under Rule 18A.05 of the Listing Rules: neither the group nor any of its partners guarantees that the relevant products will ultimately be successfully developed and marketed. The company advised shareholders and potential investors to exercise caution when dealing in its shares.
- HBM HOLDINGS-B (02142.HK): CRHX-101 Spin-Off Targets Nasdaq Listing
- HK Stock Connect Insight | HBM HOLDINGS-B (02142.HK): Batoclimab approved in China; southbound stake rises to 13.24% since Stock Connect entry on Sept 7
- HBM HOLDINGS-B (02142.HK): Partner Solstice Oncology Closes USD 225 Million Series A Financing
- HBM HOLDINGS-B (02142.HK): Positive Phase II Interim Results for HBM9378/WIN378 in Asthma; Phase III Initiated
- HBM HOLDINGS-B (02142.HK): Shares Added to Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Lists, Effective 7 September 2026